Treatment of Myeloma: Cure vs Control
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Although not often openly acknowledged, “cure versus control” is the dominant philosophical difference behind many of the strategies, trials, and debates related to the management of myeloma. Should we treat patients with myeloma with multidrug, multitransplant combinations with the goal of potentially curing a subset of patients, recognizing that the risk of adverse events and effect on quality of life will be substantial? Or should we address myeloma as a chronic incurable condition with the goal of disease control, using the least toxic regimens, emphasizing a balance between efficacy and quality of life, and reserving more aggressive therapy for later? To be sure, if cure were known to be possible (with a reasonable probability) in myeloma, it would undoubtedly be the preferred therapeutic goal of most patients and physicians. But this is not the case. Myeloma is generally not considered a curable disease; however, new definitions of cure have been suggested, including operational cure, which is defined as a sustained complete response (CR) for a prolonged period. (1,2) Cure versus control is debated because the strategies currently being tested are not truly curative but rather are intended to maximize response rates in the hope that they will translate into an operational cure for a subset of patients. For decades, the treatment of myeloma was restricted to conventional chemotherapy with alkylators and corticosteroids, and the question of cure versus control never arose. The response rate with alkylators and corticosteroids was only about 50%, and CR (3,4) was rare. Cure was never a goal of therapy because it was assumed to be unattainable. Instead, the goal was to control the disease as much as possible, providing the best quality of life to the patient for the longest duration by judicious, intermittent use of the 2 available classes of active chemotherapeutic agents. In the 1990s, high-dose therapy with autologous stem cell transplant (ASCT) became part of standard practice when it was found to prolong survival compared with conventional chemotherapy. (5-7) Subsequently, bisphosphonates were found to be effective in decreasing the incidence of bone lesions. (8,9) In the past decade, thalidomide, (10) bortezomib (11-13) and lenalidomide (14,15) emerged as effective agents for the treatment of myeloma, producing spectacular results in combination with other known agents in terms of response rate, CR rate, progression-free survival (PFS), and (more recently) overall survival. Numerous combinations have been developed, resulting in a veritable alphabet soup of clinical trials (16) and drug combinations are vying with each other for the highest response rate (and prominence). (17,18) The results obtained with new combinations have indeed been remarkable and have prompted a relatively new philosophy of treating myeloma with the goal of potential cure rather than disease control. These philosophical differences underpin the various clinically relevant debates regarding myeloma currently confronting patients and
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Self-citationInternational uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationAntitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
Rajkumar, S. V., Hayman, S. R., Lacy, M. Q., Dispenzieri, A., Geyer, S. M., Kabat, B., Zeldenrust, S. R., Kumar, S., Greipp, P. R., Fonseca, R., et al. (2005) · Blood · doi:10.1182/blood-2005-07-2817 · Cited by 648
Self-citationFermand, J.-P., Ravaud, P., Chevret, S., Divine, M., Leblond, V., Belanger, C., Macro, M., Pertuiset, E., Dreyfus, F., Mariette, X., et al. (1998) · Blood · doi:10.1182/blood.v92.9.3131 · Cited by 542
Richardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., et al. (2006) · Blood · doi:10.1182/blood-2006-04-015909 · Cited by 523
Self-citationA Comparison of Allografting with Autografting for Newly Diagnosed Myeloma
Bruno, B., Rotta, M., Patriarca, F., Mordini, N., Allione, B., Carnevale-Schianca, F., Giaccone, L., Sorasio, R., Omedè, P., Baldi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065464 · Cited by 501
Cavo, M., Tosi, P., Zamagni, E., Cellini, C., Tacchetti, P., Patriarca, F., Di Raimondo, F., Volpe, E., Ronconi, S., Cangini, D., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2509 · Cited by 370
Research works printed but not linked: 52
- Sirohi, 2001, International myeloma grand round, Lancet Oncol, 2, 571, 10.1016/S1470-2045(01)00491-0 · doi:10.1016/s1470-2045(01)00491-0
- Mehta, 2007, High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years, Bone Marrow Transplant, 40, 1101, 10.1038/sj.bmt.1705799 · DOI
- Anderson, 2008, Clinically relevant end points and new drug approvals for myeloma, Leukemia, 22, 231, 10.1038/sj.leu.2405016 · DOI · Paper page
- Barlogie, 1997, Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma, Blood, 89, 789, 10.1182/blood.V89.3.789 · DOI · Paper page
- Lacy, 2006, Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma, Mayo Clin Proc, 81, 1047, 10.4065/81.8.1047 · DOI · Paper page
- Durie, 2007, Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement [letter], Mayo Clin Proc, 82, 516, 10.4065/82.4.516 · DOI
- Richardson, 2005, Bortezomib or high-dose dexamethasone for relapsed multiple myeloma, N Engl J Med, 352, 2487, 10.1056/NEJMoa043445 · DOI · Paper page
- Cavo, 2006, Proteasome inhibitor bortezomib for the treatment of multiple myeloma, Leukemia, 20, 1341, 10.1038/sj.leu.2404278 · DOI
- Hussein, 2006, Phase 2 study of pegylated liposomal doxorubicin, vincristine, reduced schedule dexamethasone and thalidomide (DVd-T) in newly diagnosed and relapsed/refractory multiple myeloma, Mayo Clin Proc, 81, 889, 10.4065/81.7.889 · DOI
- Dispenzieri, 2007, Treatment of newly diagnosed multiple myeloma based on Mayo stratification of myeloma and risk-adapted therapy (mSMART): consensus statement, Mayo Clin Proc, 82, 323, 10.1016/S0025-6196(11)61029-X · DOI · Paper page
- Lacy, 2006, Multiple myeloma: new options, new challenges [editorial], Mayo Clin Proc, 81, 877, 10.4065/81.7.877 · DOI
- Lonial, 2007, Designing risk-adapted therapy for multiple myeloma: the Mayo perspective [editorial], Mayo Clin Proc, 82, 279, 10.1016/S0025-6196(11)61022-7 · DOI
- Adjei, 2007, Cancer symposium for the practitioner: introduction to solid tumors, Mayo Clin Proc, 82, 107, 10.1016/S0025-6196(11)60973-7 · DOI
- Tefferi, 2006, Atypical myeloproliferative disorders: diagnosis and management, Mayo Clin Proc, 81, 553, 10.4065/81.4.553 · DOI
- Quintas-Cardama, 2006, Chronic myeloid leukemia: diagnosis and treatment, Mayo Clin Proc, 81, 973, 10.4065/81.7.973 · DOI · Paper page
- Steensma, 2006, The myelodysplastic syndromes: diagnosis and treatment, Mayo Clin Proc, 81, 104, 10.4065/81.1.104 · DOI · Paper page
- Yee, 2006, Chronic lymphocytic leukemia: diagnosis and treatment, Mayo Clin Proc, 81, 1105, 10.4065/81.8.1105 · DOI
- Mauro, 2006, Stem cell transplantation in patients with chronic myelogenous leukemia: when should it be used?, Mayo Clin Proc, 81, 404, 10.4065/81.3.404 · DOI
- Wolanskyj, 2006, Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors, Mayo Clin Proc, 81, 159, 10.4065/81.2.159 · DOI · Paper page
- Aletti, 2007, Current management strategies for ovarian cancer, Mayo Clin Proc, 82, 751, 10.1016/S0025-6196(11)61196-8 · DOI · Paper page
- Steensma, 2007, Anemia in the elderly: how should we define it, when does it matter, and what can be done?, Mayo Clin Proc, 82, 958, 10.4065/82.8.958 · DOI
- Facon, 2007, Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial, Lancet, 370, 1209, 10.1016/S0140-6736(07)61537-2 · DOI · Paper page
- Barlogie, 2006, Thalidomide and hematopoietic-cell transplantation for multiple myeloma, N Engl J Med, 354, 1021, 10.1056/NEJMoa053583 · DOI · Paper page
- Landgren, 2007, Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana, Mayo Clin Proc, 82, 1468, 10.4065/82.12.1468 · doi:10.4065/82.12.1468
- Iwanaga, 2007, Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan, Mayo Clin Proc, 82, 1474, 10.4065/82.12.1474 · doi:10.4065/82.12.1474
- Rajkumar, 2006, Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment, Mayo Clin Proc, 81, 693, 10.4065/81.5.693 · DOI · Paper page
- Zhan, 2006, The role of cytogenetics in myeloma [editorial], Leukemia, 20, 1484, 10.1038/sj.leu.2404330 · DOI
- Chiecchio, 2006, Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma, Leukemia, 20, 1610, 10.1038/sj.leu.2404304 · DOI · Paper page
- Gutierrez, 2007, Leukemia, 21, 143, 10.1038/sj.leu.2404413 · DOI · Paper page
- Chng, 2006, Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations, Leukemia, 20, 807, 10.1038/sj.leu.2404172 · DOI
- Stewart, 2007, A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy, Leukemia, 21, 529, 10.1038/sj.leu.2404516 · DOI · Paper page
- Haessler, 2007, Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling, Clin Cancer Res, 13, 7073, 10.1158/1078-0432.CCR-07-0527 · DOI · Paper page
- Gertz, 2008, Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative, Mayo Clin Proc, 83, 1131, 10.4065/83.10.1131 · DOI
- Barlogie, 1999, Total therapy with tandem transplants for newly diagnosed multiple myeloma, Blood, 93, 55, 10.1182/blood.V93.1.55 · DOI · Paper page
- Attal, 2002, Double autologous transplantation improves survival of multiple myeloma patients: final analysis of a prospective randomized study of the “Intergroupe Francophone du Myelome” (IFM 94) [abstract 7], Blood, 100, 5a
- Mihelic, 2007, Maintenance therapy in multiple myeloma, Leukemia, 21, 1150, 10.1038/sj.leu.2404633 · DOI
- Lacy, 2007, Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma, Mayo Clin Proc, 82, 1179, 10.4065/82.10.1179 · DOI
- Facon, 1996, Front-line or rescue autologous bone marrow transplantation (ABMT) following a first course of high dose melphalan (HDM) in multiple myeloma (MM): preliminary results of a prospective randomized trial (CIAM protocol) [abstract 2729], Blood, 88, 685a
- Barlogie, 2003, Blood, 102, 42a
- Cavo, 2004, Superiority of double over single autologous stem cell transplantation as first-line therapy for multiple myeloma [abstract A536], Blood, 104, 155a
- Fermand, 2003, Hematol J, 4, S59
- Goldschmidt, 2003, Single vs. tandem autolgous transplantation in multiple myeloma: the GMMG experience [abstract], Hematol J, 4, S61
- Bladé, 2003, High-dose therapy autotransplantation/intensification versus continued conventional chemotherapy in multiple myeloma patients responding to initial chemotherapy: definitive results from PETHEMA after a median follow-up of 66 months [abstract 137], Blood, 102, 42a
- Rajkumar, 1999, Autologous stem cell transplantation for relapsed and primary refractory myeloma, Bone Marrow Transplant, 23, 1267, 10.1038/sj.bmt.1701805 · DOI
- Bladé, 2000, Treatment approaches for relapsing and refractory multiple myeloma, Acta Oncol, 39, 843, 10.1080/028418600750063604 · DOI · Paper page
- Bensinger, 2006, The current status of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma, Leukemia, 20, 1683, 10.1038/sj.leu.2404333 · DOI
- Crawley, 2005, Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT, Blood, 105, 4532, 10.1182/blood-2004-06-2387 · DOI · Paper page
- Garban, 2006, Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma, Blood, 107, 3474, 10.1182/blood-2005-09-3869 · DOI · Paper page
- Haessler, 2007, Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling, Clin Cancer Res, 13, 7073, 10.1158/1078-0432.CCR-07-0527 · DOI · Paper page
- Jagannath, 2007, Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials, Leukemia, 21, 151, 10.1038/sj.leu.2404442 · DOI · Paper page
- Sagaster, 2007, Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion, Leukemia, 21, 164, 10.1038/sj.leu.2404459 · DOI
- Moreau, 2007, Heterogeneity of t(4;14) in multiple myeloma: long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials, Leukemia, 21, 2020, 10.1038/sj.leu.2404832 · DOI
Cited by
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management
Rajkumar, S. V. (2022) · American Journal of Hematology · doi:10.1002/ajh.26590 · Cited by 883
“approach that emphasizes quality of life as well as OS.(93,94) Recent data show that MRD negative status (as estimated by next-generation”
BackgroundSelf-citationMultiple myeloma: 2020 update on diagnosis, risk‐stratification and management
Rajkumar, S. V. (2020) · American Journal of Hematology · doi:10.1002/ajh.25791 · Cited by 789
Self-citationKumar, S. K., Mikhael, J. R., Buadi, F. K., Dingli, D., Dispenzieri, A., Fonseca, R., Gertz, M. A., Greipp, P. R., Hayman, S. R., Kyle, R. A., et al. (2009) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0603 · Cited by 628
Self-citationMultiple myeloma: 2024 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534
Self-citationMultiple myeloma: 2016 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2016) · American Journal of Hematology · doi:10.1002/ajh.24402 · Cited by 456
Self-citation
Metadata
- Authors
- Rajkumar, S. V.
- Venue
- Mayo Clinic Proceedings
- Publisher
- Elsevier BV
- Published
- 2008-10
- Volume
- 83
- Issue
- 10
- Pages
- 1142-1145
- ISSN
- 0025-6196 (ISSN-L)
- OpenAlex
- W2169493090
- Cited by
- 73
- References
- 12
- FWCI
- 4.20
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Myeloma: Cure vs Control. https://app.cochat.ai/papers/10.4065/83.10.1142
- The paper
- Rajkumar, S. V. (2008). Treatment of Myeloma: Cure vs Control. Mayo Clinic Proceedings. https://doi.org/10.4065/83.10.1142
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.